top of page
CJC 1295(no dac) + Ipamorelin 10mg

CJC 1295(no dac) + Ipamorelin 10mg

$80.00Price
Quantity

CJC-1295 (No DAC) + Ipamorelin Protocol

CJC-1295 (No DAC), also known as Mod GRF 1-29, paired with Ipamorelin is one of the most popular growth hormone optimization protocols in peptide research.

CJC-1295 No DAC acts as a Growth Hormone Releasing Hormone (GHRH) analog, while Ipamorelin selectively stimulates the ghrelin receptor (GHSR-1a). Together, they promote natural pulsatile growth hormone release through two complementary pathways.

Unlike many older growth hormone secretagogues, Ipamorelin has minimal impact on cortisol, prolactin, or appetite, making it a cleaner option for body composition and recovery-focused protocols.

Mechanism of Action

CJC-1295 No DAC binds to GHRH receptors in the pituitary, stimulating growth hormone production and release.

Ipamorelin activates ghrelin receptors, triggering an additional growth hormone pulse through a separate signaling pathway.

Together they:

  • Amplify natural GH pulses

  • Mimic normal physiological GH secretion patterns

  • Support IGF-1 production

  • Allow receptor recovery between doses

  • Avoid sustained GH elevation associated with long-acting compounds

Potential Benefits

  • Enhanced natural growth hormone release

  • Increased lean muscle mass

  • Improved recovery and reduced soreness

  • Support for fat loss and body recomposition

  • Improved sleep quality and recovery

  • Enhanced collagen production and skin quality

  • Joint and connective tissue support

  • Minimal cortisol and prolactin elevation

  • Better long-term tolerability than many older GHRPs

Why It's Being Researched

Researchers are interested in the CJC-1295 No DAC + Ipamorelin combination because it closely mimics the body's natural growth hormone secretion pattern.

The protocol combines two complementary mechanisms of GH stimulation while avoiding many of the side effects seen with older secretagogues or direct growth hormone administration.

Although both peptides have substantial individual research, human clinical trials specifically evaluating the combination remain limited.

Interesting Facts

  • CJC-1295 No DAC was specifically designed to create pulsatile GH release rather than continuous elevation.

  • The DAC version of CJC-1295 has a dramatically longer half-life and behaves very differently.

  • Ipamorelin is considered one of the "cleanest" GH secretagogues due to minimal cortisol and prolactin stimulation.

  • Ipamorelin generally does not cause significant hunger compared with other ghrelin mimetics.

  • Twice-daily administration may better replicate natural GH pulsatility than a single daily dose.

  • Receptor sensitivity may decline with prolonged continuous use, making periodic breaks a common research strategy.

Common Research Stacks

Recovery & Performance

  • TB-500

  • BPC-157

  • Wolverine Stack

  • NAD+

Body Composition

  • Tirzepatide

  • Retatrutide

  • SLU-PP-332

  • Lipo-C

Skin & Anti-Aging

  • GHK-Cu

  • Glow Blend

  • KLOW Blend

Safety Note

CJC-1295 No DAC and Ipamorelin are investigational research compounds and have not been approved for general therapeutic use. While they are generally regarded as having a favorable side-effect profile compared with many growth hormone secretagogues, excessive GH stimulation may contribute to water retention, numbness/tingling, elevated fasting glucose, or reduced receptor responsiveness with prolonged use. Individual response can vary considerably.

RESEARCH PURPOSES ONLY

NOT AVAILABLE FOR HUMAN CONSUMPTION

    bottom of page